JOHNSON & Johnson says fourth-quarter profit jumped 19 per cent, as prescription drug sales climbed sharply and the health care giant enjoyed a big tax benefit.
The maker of baby shampoo, biological drugs and medical devices also benefited from the turnaround of its consumer health care business, which rebounded with rising sales of US sales of Tylenol, Motrin and other brands.
Those had been off store shelves for a few years because of dozens of product recalls dating back to 2009 and the closure of a key factory that's been gutted and rebuilt but hasn't reopened yet.
J&J said fourth-quarter net income was $US3.52 billion ($A4.01 billion), or $US1.23 per share, up from $US2.57 billion, or 91 cents per share, a year earlier.
Excluding one-time items, net income was $US3.56 billion, or $US1.24 per share. Analysts surveyed by FactSet were expecting, on average, earnings per share of $US1.20.
Revenue totalled $US18.36 billion, up 4.5 per cent from $US17.56 billion a year ago. Analysts expected $US17.94 billion.
Sales of prescription drugs rose 12 per cent to $US7.3 billion, including an 18 per cent jump in US sales. They were led by immune disorder drugs Remicade, Stelara and Simponi, as well as HIV drug Prezista and the injected schizophrenia drug Invega Sustena.
Consumer product sales rose 2.8 per cent to $US3.75 billion, while sales of medical devices and diagnostics dipped one per cent.
The company, based in New Brunswick, New Jersey, said it expects earnings per share of $US5.75 to $US5.85 in 2014. That's up from $US4.81 per share earned in 2013.
Anda sedang membaca artikel tentang
Johnson & Johnson's 4Q profit rises 19%
Dengan url
https://tikusinternet.blogspot.com/2014/01/johnson-johnsons-4q-profit-rises-19.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Johnson & Johnson's 4Q profit rises 19%
namun jangan lupa untuk meletakkan link
Johnson & Johnson's 4Q profit rises 19%
sebagai sumbernya
0 komentar:
Posting Komentar